Literature DB >> 11702612

Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management.

M Murphy1, A J Carmichael.   

Abstract

Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and variable absorption as well as improved patient compliance. Drugs currently available by this route include scopolamine, nitroglycerin (glyceryl trinitrate), estradiol, nicotine, clonidine, fentanyl, and testosterone. This novel development has brought about a specific constellation of skin problems which vary widely in incidence between drugs. It is important to vary the site of drug administration to minimize these reactions. Any eczematous reaction can be treated with a moderately potent topical corticosteroid. Patients with topical sensitivity are usually tolerant of oral challenge but systemic sensitization has been reported and caution is still advocated before proceeding to this step. The increasing use of transdermal drug delivery systems across many specialities means that problems of skin sensitivity are of growing relevance to the dermatologist, the hospital specialist, and the primary care physician.

Entities:  

Mesh:

Year:  2000        PMID: 11702612     DOI: 10.2165/00128071-200001060-00004

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  11 in total

1.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

2.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

3.  Management of overactive bladder with transdermal oxybutynin.

Authors:  Jonathan S Starkman; Roger R Dmochowski
Journal:  Rev Urol       Date:  2006

Review 4.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

5.  The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence.

Authors:  A E Bharucha; B M Seide; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2010-09       Impact factor: 8.171

6.  Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

Authors:  Jeffrey L Cummings; Martin R Farlow; Xiangyi Meng; Sibel Tekin; Jason T Olin
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Transdermal therapy for overactive bladder: present and future.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2003

Review 8.  Challenges and opportunities in dermal/transdermal delivery.

Authors:  Kalpana S Paudel; Mikolaj Milewski; Courtney L Swadley; Nicole K Brogden; Priyanka Ghosh; Audra L Stinchcomb
Journal:  Ther Deliv       Date:  2010-07

9.  Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 chinese cancer patients.

Authors:  Yu-Lin Zhu; Guo-Hong Song; Duan-Qi Liu; Xi Zhang; Kui-Feng Liu; Ai-Hua Zang; Ying Cheng; Guo-Chun Cao; Jun Liang; Xue-Zhen Ma; Xin Ding; Bin Wang; Wei-Lian Li; Zuo-Wei Hu; Gang Feng; Jiang-Jin Huang; Xiao Zheng; Shun-Chang Jiao; Rong Wu; Jun Ren
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

Review 10.  Use of transdermal drug formulations in the elderly.

Authors:  Laure-Zoé Kaestli; Anne-Florence Wasilewski-Rasca; Pascal Bonnabry; Nicole Vogt-Ferrier
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.